Ofer Shpilberg

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Vesalius Ventures, Inc (Vesalius Ventures) is a venture capital firm founded in 2002. The firm is headquartered in Houston, Texas.

Concord Venture Management Ltd. (Concord) is a venture capital firm founded in 1992 by Yair Safrai and Matty Karp. The firm is headquartered in Herzelia, Israel.

Medica Venture Partners (Medica Venture Partners) is a venture capital firm founded in 1995 by Yuval Binur, Ehud Geller and Jonathan Fleming. The firm is headquartered in Israel.

LifeOnKey, Inc. provides online personal healthcare management systems. It offers LifeOnKey, a mobile and web-based solution that enables monitoring patients including mobile and web applications for the healthcare providers, the patients, and informal caregivers, that have been authorized by the patients. The company was founded by Linda E. Harnevo and Moshe Farin in 2003 and is headquartered in New York, NY.

Expanding Orthopedics, Inc. develops and markets orthopedic device products. The firm’s products include XPED pedicle screw system and FLXfit 3D expandable Cage. The company was founded by Mark M. Levy in 2001 and is headquartered in Atlanta, GA.

Opal Ventures (Opal Ventures) is a private equity firm founded by Batsheva Elranin in 1900. The firm is headquartered in Israel.

OurCrowd Management Ltd (OurCrowd) is a venture capital firm founded in 2013 by Jonathan Medved and Steven Blumgart. The firm is headquartered in Jerusalem, Israel.

Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel.

HIL Applied Medical Ltd. develops cancer Proton Therapy systems. It applies a patented approach, combining nanotechnology, and high-intensity lasers for its solutions. The company was founded by Shmuel Eisenmann and Arie Zigler in 2010 and is headquartered in Jerusalem, Israel.

Nanolabz, Inc. develops a technology system for cancer proton radiation therapy. It develops and sells laser physics targets for the short-pulse laser research and development sector. The company was founded by Steven Malekos, Jesse Adams, and Grant Korgan and is headquartered in Sparks, NV.

BrainQ Technologies Ltd. develops a detection and non-invasive treatment technology to help patients with paralysis move their limbs. The company was founded by Segal Yaron, Drechsler Yotam, and Shohami Emerita Esther on August 14, 2011 and is headquartered in Jerusalem, Israel.

DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014.

OurCrowd Medtech Fund invests in companies located in Israel. The fund targets operating in the fields of medical devices, therapeutics, medical robotics. It provides financing for early stage capital requirements.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.